Dr. Mileham Discusses Biomarkers in Lung Cancer

Kathryn Mileham, MD
Published: Wednesday, Dec 13, 2017



Kathryn Mileham, MD, medical oncologist, Levine Cancer Institute, Carolinas HealthCare System, discusses biomarkers in lung cancer.

The landscape of lung cancer has changed tremendously over the past 20 years, says Mileham. With the discovery of numerous mutations, the development of biomarkers and biomarker testing has blossomed.

Mileham says that the established biomarkers that are predictive in response for non–small cell lung cancer are ALK, ROS1, EGFR, BRAF, and PD-L1.
 


Kathryn Mileham, MD, medical oncologist, Levine Cancer Institute, Carolinas HealthCare System, discusses biomarkers in lung cancer.

The landscape of lung cancer has changed tremendously over the past 20 years, says Mileham. With the discovery of numerous mutations, the development of biomarkers and biomarker testing has blossomed.

Mileham says that the established biomarkers that are predictive in response for non–small cell lung cancer are ALK, ROS1, EGFR, BRAF, and PD-L1.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Leveraging Liquid Biopsies in Tumor Characterization for NSCLC TherapyJan 31, 20181.5
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Publication Bottom Border
Border Publication
x